Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing immunotherapies for cancer. The company has historically worked on early-stage product candidates and is now seeking new candidates and licensing or acquisition opportunities to rebuild its pipeline.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEarly-stage programs aimed at developing cancer immunotherapies and related product candidates.
Rights acquisition and licensing activities used to source new therapeutic candidates.
Limited advisory and related services performed under service agreements such as the Oncotelic MSA.
Customers
The company does not appear to have a broad commercial customer base yet, as it remains focused on development-stage biotechnology activities. Its current revenue, where present, comes from advisory and related services rather than product sales, while future customers would likely be patients, physicians, and healthcare systems if a therapy is commercialized. In the near term, counterparties include licensing partners, investors, and service clients that support funding and pipeline development.
Biotech or pharma counterparties that may provide product candidates or rights for Mosaic to develop.
Organizations such as Oncotelic that purchase advisory and related services for studies and projects.
Equity and debt investors that fund operations because the company has limited operating cash flow.
Patients, physicians, and healthcare systems that would use approved immunotherapies if development succeeds.
Strategy
Mosaic's strategy is to preserve liquidity while seeking new product candidates and rights that can rebuild a viable oncology pipeline. Management also expects to rely on equity and/or debt financing, but the filings emphasize that funding is uncertain and may force further scaling back if capital is not available.
The company needs new candidates to create a development pipeline and future value.
Operations and R&D cannot scale without external financing.
Limited cash has forced the company to delay and scale back programs.
Geography
The company is based in the United States and its reported activity is centered there. No country-level revenue disclosure was provided, and the available filings do not indicate a meaningful international operating footprint. As a result, Mosaic's business exposure appears concentrated in the U.S. capital markets, U.S. regulatory environment, and U.S.-based development and service relationships.
Risks
The company faces substantial going-concern and financing risk because it has limited cash, no committed funding plan, and ongoing losses. Its development-stage model also creates execution risk: if it cannot source attractive assets, advance them efficiently, or raise capital on acceptable terms, it may have to cease operations. Like other biotech firms, it is also exposed to clinical, regulatory, and valuation uncertainty around early-stage programs and acquired rights.
The company states it may cease operations if it cannot raise sufficient capital.
Management expects to fund operations through equity and/or debt, both of which may be costly.
Exposure: Existing shareholders and future operating flexibility
Value depends on identifying and advancing new product candidates or licensed rights.
Exposure: Research and development strategy
Immunotherapy development is uncertain and subject to trial, approval, and commercialization setbacks.
Exposure: Future product viability
Accounting
Judgemental itemsManagement says substantial doubt exists about continuing operations without new funding.
Impact: Can influence disclosure, asset recoverability, and investor perception
The unsecured convertible note includes interest and conversion features that affect liabilities and equity.
Impact: Creates non-cash interest expense and possible dilution
Cash flow statements show large increases in accrued compensation offsetting losses.
Impact: Affects working capital and reported operating cash flow
The company earned advisory fees under a master services agreement, which must be recognized when earned.
Impact: Affects other income and comparability across periods
Similar listed companies
Publicly listed companies with a comparable business focus.
Immuneering Corp
IMRX · Pharmaceutical Preparations
Immuneering Corp is a clinical-stage biotechnology company focused on developing oncology therapies, with an emphasis on MAPK pathway cancers and biomarker-driven patient selection.
The Mosaic Company
MOS · Agricultural Chemicals
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
MAIA Biotechnology, Inc.
MAIA · Pharmaceutical Preparations
LeonaBio, Inc.
LONA · Biological Products, (No Diagnostic Substances)
Immunic, Inc
IMUX · Pharmaceutical Preparations
Last updated: 24/09/2026